An imbalance between oxidants and antioxidants is considered to play a role in the
pathogenesis of chronic obstructive pulmonary disease (COPD). There is considerable …

The addition of an inhaled long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS)
gives optimal control of asthma in most patients and two fixed combination inhalers …

ELR+ CXC chemokines, by direct interaction with their cell surface receptors CXC
chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2), are believed to …

No currently available treatments have been shown to slow the progression of chronic
obstructive pulmonary disease (COPD) or suppress the inflammation in small airways and …

Orally inhaled products have well-known benefits. They allow for effective local
administration of many drugs for the treatment of pulmonary disease, and they allow for …

COPD is one of the most common diseases in the world, and there is a global increase in
prevalence, but there are no drugs available at present that halt the relentless progression of …

Despite being the most common respiratory disorder in the developed world and the fourth
leading cause of death in the US, chronic obstructive pulmonary disease (COPD) has …

Allergen‐specific immunotherapy (SIT) is the only specific and disease‐modifying approach
for the treatment of allergy but several disadvantages have limited its broad applicability. We …

Drugs currently available or under development for the treatment of chronic obstructive
pulmonary disease (COPD) are reviewed. More research on the basic cellular and …

Tiotropium bromide (Spiriva, BA679BR, Boehringer Ingelheim) is a novel inhaled, long-
acting anticholinergic bronchodilator that is employed as a once-daily maintenance …